Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes

被引:50
作者
Gibb, Fraser W. [1 ,2 ]
McKnight, John A. [3 ]
Clarke, Catriona [4 ]
Strachan, Mark W. J. [3 ]
机构
[1] Royal Infirm Edinburgh NHS Trust, Edinburgh Ctr Endocrinol & Diabet, Edinburgh EH16 4SA, Midlothian, Scotland
[2] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[3] Western Gen Hosp, Edinburgh Ctr Endocrinol & Diabet, Edinburgh, Midlothian, Scotland
[4] Western Gen Hosp, Dept Clin Biochem, Edinburgh, Midlothian, Scotland
关键词
Clinical diabetes; Continuous glucose monitoring; C-peptide; Devices; Hypoglycaemia; GLUCAGON-RESPONSE; INTRAISLET INSULIN; HYPOGLYCEMIA; COMPLICATIONS; FREQUENCY; DIAGNOSIS; AWARENESS; DECREMENT; DURATION; ONSET;
D O I
10.1007/s00125-020-05099-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis We aimed to assess whether persistence of C-peptide secretion is associated with less glucose variability and fewer low-glucose events in adults with type 1 diabetes who use flash monitoring. Methods We performed a cross-sectional study of 290 adults attending a university teaching hospital diabetes clinic, with type 1 diabetes, who use flash monitoring and in whom a random plasma C-peptide was available in the past 2 years. Variables relating to flash monitoring were compared between individuals with low C-peptide (<10 pmol/l) and those with persistent C-peptide (either 10-200 pmol/l or 10-50 pmol/l). In addition, the relationship between self-reported hypoglycaemia and C-peptide was assessed (n = 167). Data are median (interquartile range). Results Individuals with preserved C-peptide secretion (10-200 pmol/l) had shorter duration of diabetes (15 [9-24] vs 25 [15-34] years, p < 0.001) and older age at diagnosis (23 [14-28] vs 15 [9-25] years, p < 0.001), although current age did not differ in this cohort. Preserved C-peptide was associated with lower time with glucose <3.9 mmol/l (3% [2-6%] vs 5% [3-9%], p < 0.001), fewer low-glucose events per 2 week period (7 [4-10] vs 10 [5-16], p < 0.001), lower SD of glucose (3.8 [3.4-4.2] vs 4.1 [3.5-4.7] mmol/l, p = 0.017) and lower CV of glucose (38.0 [35.0-41.6] vs 41.8 [36.5-45.8], p < 0.001). These differences were also present in those with C-peptide 10-50 pmol/l and associations were independent of diabetes duration and estimated HbA(1c) in logistic regression analysis. Preserved C-peptide was also associated with lower rates of self-reported asymptomatic hypoglycaemia (8.0% vs 22.8% in the past month, p = 0.028). Conclusions/interpretation Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash monitoring. This suggests that individuals with preserved C-peptide may more safely achieve intensive glycaemic targets.
引用
收藏
页码:906 / 914
页数:9
相关论文
共 24 条
[11]   Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic [J].
Hope, S. V. ;
Knight, B. A. ;
Shields, B. M. ;
Hattersley, A. T. ;
McDonald, T. J. ;
Jones, A. G. .
DIABETIC MEDICINE, 2016, 33 (11) :1554-1558
[12]   Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia [J].
Hope, Suzy V. ;
Knight, Bridget A. ;
Shields, Beverley M. ;
Hill, Anita V. ;
Choudhary, Pratik ;
Strain, W. David ;
McDonald, Timothy J. ;
Jones, Angus G. .
DIABETOLOGIA, 2018, 61 (01) :66-74
[13]   The clinical utility of C-peptide measurement in the care of patients with diabetes [J].
Jones, A. G. ;
Hattersley, A. T. .
DIABETIC MEDICINE, 2013, 30 (07) :803-817
[14]   Low levels of C-peptide have clinical significance for established Type 1 diabetes [J].
Kuhtreiber, W. M. ;
Washer, S. L. L. ;
Hsu, E. ;
Zhao, M. ;
Reinhold, P., III ;
Burger, D. ;
Zheng, H. ;
Faustman, D. L. .
DIABETIC MEDICINE, 2015, 32 (10) :1346-1353
[15]   Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial [J].
Lachin, John M. ;
McGee, Paula ;
Palmer, Jerry P. .
DIABETES, 2014, 63 (02) :739-748
[16]   Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice? [J].
Marren, S. M. ;
Hammersley, S. ;
McDonald, T. J. ;
Shields, B. M. ;
Knight, B. A. ;
Hill, A. ;
Bolt, R. ;
Tree, T. I. ;
Roep, B. O. ;
Hattersley, A. T. ;
Jones, A. G. ;
Oram, R. A. .
DIABETIC MEDICINE, 2019, 36 (09) :1092-1099
[17]   Hypoglycemia in Type 1 Diabetes [J].
McCrimmon, Rory J. ;
Sherwin, Robert S. .
DIABETES, 2010, 59 (10) :2333-2339
[18]   Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes - Documentation of the intraislet insulin hypothesis in humans [J].
Raju, B ;
Cryer, PE .
DIABETES, 2005, 54 (03) :757-764
[19]   Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes [J].
Sherr, Jennifer ;
Xing, Dongyuan ;
Ruedy, Katrina J. ;
Beck, Roy W. ;
Kollman, Craig ;
Buckingham, Bruce ;
White, Neil H. ;
Fox, Larry ;
Tsalikian, Eva ;
Weinzimer, Stuart ;
Arbelaez, Ana Maria ;
Tamborlane, William V. .
DIABETES CARE, 2013, 36 (06) :1470-1476
[20]   C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase [J].
Shields, Beverley M. ;
McDonald, Timothy J. ;
Oram, Richard ;
Hill, Anita ;
Hudson, Michelle ;
Leete, Pia ;
Pearson, Ewan R. ;
Richardson, Sarah J. ;
Morgan, Noel G. ;
Hattersley, Andrew T. .
DIABETES CARE, 2018, 41 (07) :1486-1492